Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a one-year extension study of the use of laronidase into the spinal fluid to treat spinal cord compression in mucopolysaccharidosis I. Mucopolysaccharidosis I is a rare genetic condition due to deficiency of the enzyme alpha-l-iduronidase. Spinal cord compression occurs in this condition due to accumulation of material called glycosaminoglycans (GAG). Laronidase is the manufactured form of the enzyme alpha-l-iduronidase that is deficient in mucopolysaccharidosis I patients. The aim of this study is to determine whether laronidase is safe and effective when given into the spinal fluid as a potential non-surgical treatment for spinal cord compression due to mucopolysaccharidosis I disease. Funding Source -- FDA OOPD
| Condition | Intervention | Phase |
|---|---|---|
|
Spinal Cord Compression Mucopolysaccharidosis I Hurler-Scheie Syndrome Scheie Syndrome Lysosomal Storage Disease |
Drug: laronidase |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Extension Study of Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis I |
- safety of intrathecal enzyme treatment by blood and spinal fluid tests; improvement or stabilization in neurologic signs and symptoms of spinal cord compression [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
| Enrollment: | 3 |
| Study Start Date: | January 2008 |
| Study Completion Date: | October 2011 |
| Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: intrathecal laronidase
drug laronidase, dose 1.74 mg, route intrathecal, frequency every 30-90 days, duration 1 year
|
Drug: laronidase
1.74 mg intrathecally every 1-3 months for 1 year
Other Names:
|
Detailed Description:
Enzyme replacement therapy (ERT) has been developed for mucopolysaccharidosis I (MPS I), a lysosomal storage disorder. ERT helps many physical ailments due to the disease, but does not treat the central nervous system, due to inability to cross the blood brain barrier. Our purpose is to test delivery of ERT to the spinal fluid via intrathecal injection in patients with MPS I. In this pilot study, we will use recombinant human α-L-iduronidase administered intrathecally once per month for four months to individuals with the Hurler-Scheie and Scheie forms of MPS I and spinal cord compression. If successful, intrathecal delivery could represent a practical, straightforward method of treating central nervous system disease due to lysosomal storage.
Eligibility| Ages Eligible for Study: | 8 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Hurler-Scheie, Scheie form of MPS I, or Hurler 2 years after hematopoietic stem cell transplantation
- Spinal cord compression
- Has received intrathecal laronidase previously with good response and no significant safety concerns
- Age greater than 8 years
- Able to provide legal informed consent
- Aware of clinical treatment option of observation without treatment or surgical decompression
- Negative urine pregnancy test at screening (nonsterile females of child-bearing potential who are sexually active only)
Exclusion Criteria:
- Severe (Hurler) form of MPS I
- Desires surgical or medical treatment of spinal cord compression
- Spinal cord compression that warrants immediate surgical intervention
- Pregnancy or lactation
- Hematopoietic stem cell transplantation within 2 years of study enrollment
- Receipt of an investigational drug within 30 days of enrollment
- Infusion reactions to laronidase that required medical intervention, prophylaxis, or altered enzyme administration
- Significant anti-iduronidase antibody titer
- Recent initiation of intravenous laronidase (within past 6 months)
- Presence of cervical subluxation or similar external pathology as the major cause of cord compression symptoms for which surgical intervention should be immediately undertaken
Contacts and Locations| United States, California | |
| Los Angeles Biomedical Research Institute at Harbor-UCLA | |
| Torrance, California, United States, 90502 | |
| Finland | |
| Helsinki University Central Hospital | |
| Helsinki, Finland | |
| Principal Investigator: | Patricia I Dickson, MD | Los Angeles Biomedical Research Institute at Harbor-UCLA |
More Information
No publications provided
| Responsible Party: | Patricia I. Dickson, M.D., Associate Professor of Pediatrics, Dickson, Patricia I., M.D. |
| ClinicalTrials.gov Identifier: | NCT00786968 History of Changes |
| Other Study ID Numbers: | MIRC-001-01 |
| Study First Received: | June 17, 2008 |
| Last Updated: | February 19, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Dickson, Patricia I., M.D.:
|
mucopolysaccharidosis Hurler-Scheie Scheie laronidase |
spinal cord compression central nervous system enzyme replacement therapy intrathecal |
Additional relevant MeSH terms:
|
Mucopolysaccharidosis I Mucopolysaccharidoses Spinal Cord Compression Lysosomal Storage Diseases Metabolic Diseases Carbohydrate Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn |
Mucinoses Connective Tissue Diseases Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases Spinal Cord Injuries Wounds and Injuries |
ClinicalTrials.gov processed this record on June 18, 2013